| irinotecan / Generic mfg. |
ACTRN12624000079549: PhaRmacogEnomiC medIcines optimiSatIon for peOple with caNcer – a multicentre teletrial enabled Interrupted Time Series trial (PRECISION-ITS): Pharmacogenomics primary study and discovery program |
|
|
| Not yet recruiting | N/A | 1470 | | | Peter MacCallum Cancer Centre , Peter MacCallum Cancer Centre , Department of Health and Aged care (Medical research future fund) | Cancer and other malignant neoplasms | | | | |
ACTRN12623001301651: GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients
|
|
|
| Not yet recruiting | N/A | 5000 | | | Hunter Medical Research Unit, National Health and Medical Research Council | Cancer, Fluoropyrimidine chemotherapy toxicity, DPD deficiency, DPYD gene variant, UGT1A1 gene variant | | | | |
ChiCTR-OPC-15006819: S-1 and raltitrexed for patients with metastatic colorectal cancer after failure to fluoropyrimidine, irinotecan and oxaliplatin. |
|
|
| Completed | N/A | 30 | | S-1 and raltitrexed | Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University.; Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University., Research Fund of West China Hospital | colorectal cancer | | | | |
ChiCTR2000036967: Study on differences in intestinal flora of patients with relapsed/refractory neuroblastoma in children with different responses to irinotecan combined with temozolomide |
|
|
| Recruiting | N/A | 150 | | Irinotecan combined with temozolomide ;Nil | Xinhua Hospital affiliated to Shanghai Jiao Tong University School Of Medicine; Xinhua Hospital affiliated to Shanghai Jiao Tong University School Of Medicine, Hospital Development Center | Recurrent/refractory neuroblastoma in children | | | | |
NCT06129812: An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer |
|
|
| Completed | N/A | 1132 | NA | Neoadjuvant treatment | Seoul National University Hospital | Pancreatic Cancer, Neoadjuvant | 12/21 | 12/21 | | |
ChiCTR1900026360: FOLFIRI plus cetuximab as first-line therapy followed by cetuximab maintenance therapy in patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: a single institute study |
|
|
| Completed | N/A | 60 | | cetuximab 500 mg/m2 d1, combined with irinotecan 180 mg/m2 d1, intravenous drip 90 min d1, every 2 weeks as a cycle, record the disease control. In the maintenance phase1 group, if reach disease control (PR, CR, SD) after 6-12 cycles of treatment, according to the adverse effects of patients and per ;Nil | Medical Oncology Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, self-raised funds | Colorectal Cancer | | | | |
ChiCTR-ONC-16009325: Clinical study of irinotecan and platinum sequential chemotherapy with EP in the treatment of extensive stage small cell lung cancer |
|
|
| Not yet recruiting | N/A | 40 | | Etoposide (VP-16), 100/m2, intravenous drip, D1 ~ D3; cisplatin (DDP), 25 mg/m2, intravenous drip, D1 ~ D3 days. 21 d for 1 cycles, 4 cycles. | Huangshi Central Hospital; Huangshi Central Hospital, Self-financing | small cell lung cancer | | | | |
ChiCTR-INR-16009947: Phase II study of Compound Formula Realgar-Indigo Naturalis as second-line therapy in late-stage gastric cancer patients |
|
|
| Not yet recruiting | N/A | 216 | | Compound Realgar NaturalIndigo Tablet combined with irinotecan; placebo combined with irinotecan | Xinhua Hospital, Affiliated to School of Medicine, Shanghai Jiaotong University; Xinhua Hospital, Shanghai Hospital Development Center | gastric cancer | | | | |
ChiCTR1800016151: Efficacy and safety of irinotecan combined with systemic chemotherapy in the treatment of cervical cancer with CalliSpheres loaded drug embolization microspheres: a prospective, single center clinical trial |
|
|
| Recruiting | N/A | 80 | | CalliSpheres loaded drug embolic microspheres loaded with irinotecan with DEB-TACE | Department of gynaecology in the west coast of Affiliated Hospital of Qingdao University Medical College; Department of gynaecology in Affiliated Hospital of Qingdao University Medical College, Jiangsu hengrui pharmaceutical co. LTD. | Cervical cancer | | | | |
ChiCTR1800017622: Clinical observation of the effects of Scutellaria decoction combined with 5-FU and irinotecan in the treatment of metastatic colorectal cancers with damp-heat syndrome pattern |
|
|
| Recruiting | N/A | 60 | | modified Scutellaria decoction+5-FU+irinotecan ;5-FU+irinotecan | Eighth People's Hospital of Shanghai; Eighth People's Hospital of Shanghai, program of integrated traditional Chinese and Western medicine in Shanghai | colorectal cancer | | | | |
ChiCTR1900021845: CalliSpheres microspheres for the treatment of liver metastases from colorectal cancer: the effect of irinotecan on the HIF-1α pathway and its anti-tumor effect |
|
|
| Not yet recruiting | N/A | 20 | | Callispheres microspheres were loaded with 100 mg irinotecan for the embolization, and surgical resection of metastases at different time points ;Callispheres microspheres were loaded with 200 mg irinotecan for the embolization, and surgical resection of metastases at different time points ;Callispheres microspheres were loaded with 400 mg irinotecan for the embolization, and surgical resection of metastases at different time points ;After the examination is completed, the liver metastases are directly removed. | Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China Health Promotion Foundation Cancer Intervention Research Fund XM_2018_011_0006_01, 150,000 yuan; Wuhan Municipal Health and Family Planning Commission project - key project S201803010039, 50,000 | Colorectal cancer liver metastasis | | | | |
ChiCTR1900021388: Single-center clinical study for embolization with irinotecan loaded microspheres in the treatment of hepatic metastasis from neuroendocrine carcinoma |
|
|
| Not yet recruiting | N/A | 50 | | DEB-IRI | Beijing Cancer Hospital; Beijing Cancer Hospital, China Health Promotion Foundation | neuroendocrine carcinoma | | | | |
NCT04305288: Chemotherapy mFOLFIRINOX in Locally Advanced or Metastatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | | Shanghai Jiao Tong University School of Medicine | Cholangiocarcinoma of the Bile Duct | 12/20 | 12/21 | | |
NCT04446793: Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer |
|
|
| No Longer Available | N/A | | NA | Onvansertib, Bevacizumab, FOLFIRI | Cardiff Oncology | Metastatic Colorectal Cancer, KRAS Gene Mutation | | | | |
ChiCTR2000029201: A medical records based study for selection of medicine depends on clinical characteristics between fluorouracil combined with oxaliplatin and irinotecan regimens and their effects on patients' life quality |
|
|
| Recruiting | N/A | 1400 | | mFOLFOX6 ;FOLFIRI | The First Affiliated Hospital of College of Medicine, Zhejiang University; The First Affiliated Hospital of College of Medicine, Zhejiang University, Raise Independently | Tumour | | | | |
ChiCTR1900024012: Clinical study of FOLFIRI regimen combined with apatinib in the treatment of advanced rectal cancer during perioperative period |
|
|
| Not yet recruiting | N/A | 240 | | Apatinib combined with FOLFIRI | Shanxi Provincial Cancer Hospital; Shanxi Provincial Cancer Hospital, None | colorectal cancer | | | | |
ChiCTR1900026961: An Exploratory Study for the Efficacy and Safety of Cetuximab in Combination with Irinotecan Re-challenge Versus Regorafenib in the Third-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 60 | | Cetuximab-targeted combination with irinotecan chemotherapy, the specific regimen is as follows: Cetuximab (trade name: Erbitux) once every two weeks, 500 mg/m2, d1; Irinotecan 180 mg/m2 ivgtt 90 min d1 q2w ;Regorafenib oral treatment, the specific regimen is as follows: regorafenib 120 mg d1-21 q4w | Fujian Medical University Union Hospital; Level of the institution：, Joint Funds for the innovation of science and Technology, Fujian province | Colorectal Cancer | | | | |
NCT03286738: Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 1800 | RoW | FOLFIRI, target agent | Joong Bae Ahn | Metastatic Colorectal Cancer | 12/21 | 12/21 | | |
ChiCTR2000040940: Medical Records Based Real-World Study of Cetuximab in Combination with FOLFIRI Regimen as First-Line Chemotherapy and Subsequent Cetuximab-based Maintenance Therapy for the Maintenance Treatment of Patients with RAS and BRAF Wild-Type Unresectable Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 100 | | Nil | Medical Oncology Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, self-raised funds | Colorectal Cancer | | | | |
ChiCTR2000028857: Clinical study of carelizumab combined with apatinib and irinotecan in the second-line treatment of advanced esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 65 | | Carelizumab combined with apatinib and irinotecan | The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology of China, Self-raised | Esophageal squamous cell carcinoma | | | | |
NCT04996355: Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs |
|
|
| Recruiting | N/A | 52 | RoW | comprehensive treatment after MDT discussion | Peking University People's Hospital, Peking University | Colorectal Neoplasms, Organoids | 05/22 | 05/24 | | |
ChiCTR1900021862: A randomized controlled trial for irinotecan-eluting beads transarterial chemoembolization with systemic GEMOX (gemcitabine plus oxaliplatin) versus GEMOX in patients with unresectable, local advanced or metastatic intrahepatic cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 150 | | irinotecan DEB-TACE with GEMOX ;GEMOX treatment | Zhongshan Hospital of Fudan University; Zhongshan Hospital of Fudan University, Fund for Clinical Research, Zhongshan Hospital of Fudan University | intrahepatic cholangiocarcinoma | | | | |
NCT06378580: The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma |
|
|
| Completed | N/A | 72 | RoW | Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX | Luo Cong | Pancreatic Cancer | 07/23 | 04/24 | | |
NCT05688033: Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy |
|
|
| Active, not recruiting | N/A | 200 | RoW | dosimetric limitation of pelvic bone and peritoneal space during radiotherapy | Fudan University | Rectal Cancer | 08/22 | 12/23 | | |
ChiCTR2000037448: Anlotinib combined with irinotecan in second-line and above treatment of HER-2 negative advanced breast cancer |
|
|
| Not yet recruiting | N/A | 36 | China | Focus V (anlotinib) - Advenchen, Sino Biopharm, irinotecan - Generic mfg. | The Affiliated Hospital of Jiangnan University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast cancer | | | | |
ChiCTR1900027610: An Umbrella Study to Explore Precision Treatment of Colorectal Cancer Based on Molecular Typing |
|
|
| Not yet recruiting | N/A | 60 | | Trastuzumab + Camrelizumab + Irinotecan ;Cetuximab + Pyrotinib + Irinotecan ;Cetuximab + MEK Inhibitor + Irinotecan ;PARP Inhibitor + Irinotecan | Shanghai East Hospital; Shanghai East Hospital, Expenditure of department | Colorectal Cancer | | | | |
AIP2021, NCT05507736: Feasibility and Safety of Acupuncture in the Prevention of Late Irinotecan-related Diarrhea in Pediatric Patients |
|
|
| Recruiting | N/A | 21 | Europe | Acupuncture, Indwelling, sterile and disposable needles (SEIRIN NEW PYONEX®) | Fundació Sant Joan de Déu | Pediatric Cancer, Solid Tumor | 09/22 | 12/22 | | |
| Active, not recruiting | N/A | 70 | Europe | Irinotecan-Eluting Beads, DEBIRI | Federation Francophone de Cancerologie Digestive | Colorectal Adenocarcinoma, Hepatic Metastases | 10/22 | 10/22 | | |
NCT04423731: Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | N/A | 251 | Europe | Folfirinox, Gemcitabine/nab-paclitaxel, Gemcitabine, 5-FU (fluorouracil) and leucovorin, FLOX | Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, Helse Stavanger HF | Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatectomy | 10/22 | 12/25 | | |
ChiCTR1800018694: A prospective study of irinotecan drug-eluting beads (DEBIRI) combined with FOLFIRI in patients after failure of FOLFOX with colorectal liver metastases |
|
|
| Not yet recruiting | N/A | 30 | | DEBIRI+FOLFIRI | Guangdong General Hospital; Guangdong General Hospital, Self-financing | colorectal cancer | | | | |
NCT05027100: Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC |
|
|
| Recruiting | N/A | 33 | RoW | Anlotinib Tislelizumab Irinotecan | Haibo Zhang | Small Cell Lung Cancer (SCLC) | 12/22 | 06/23 | | |
ChiCTR1800018908: Microbiological metabolomics of fecal samples in colorectal cancer patients |
|
|
| Not yet recruiting | N/A | 200 | | FOLFIRI regimen ;FOLFIRI regimen ;No | Huzhou Central Hospital; Huzhou Central Hospital, Self-financing | Colorectal Cancer | | | | |
ChiCTR1900024597: Ketogenic diet combined with irinotecan is available for promoting chemotherapy sensitivity and reducing target lesions in patients with locally recurrent or metastatic Her-2 negative breast cancer: a randomized controlled trial |
|
|
| Not yet recruiting | N/A | 518 | | irinotecan + ketogenic diet ;irinotecan + normal diet | Liaoning Cancer Hospital & Institute; Liaoning Cancer Hospital & Institute, None | locally recurrent or metastatic Her-2 negative breast cancer | | | | |
NCT05248022: Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure |
|
|
| Not yet recruiting | N/A | 98 | NA | Drug-eluting beads bronchial arterial chemoembolization, Programmed Cell Death Protein 1 Inhibitor | The Central Hospital of Lishui City, Jiangxi Provincial Cancer Hospital, Jiangxi Chest Hospital, The First Affiliated Hospital of Zhengzhou University, Zhejiang University | Carcinoma, Non-Small-Cell Lung | 12/24 | 12/24 | | |
| Not yet recruiting | N/A | 240 | Europe | Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation, DEBIRI, DEB TACE | The Christie NHS Foundation Trust | Colorectal Cancer Metastatic, Liver Metastases | 01/23 | 01/24 | | |
NCT05262452: Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer |
|
|
| Recruiting | N/A | 60 | RoW | ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen | Seoul National University Hospital, Focused Ultrasound Foundation, Synex Consulting Ltd | Pancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound Therapy | 03/23 | 12/24 | | |
NCT05178745: A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection |
|
|
| Completed | N/A | 140 | NA | Fluorouracil, Aflibercept, ZALTRAP®, Irinotecan, CAMPTOSAR® | Sanofi | Metastatic Colorectal Cancer, Colorectal Neoplasms | 05/22 | 05/22 | | |
NCT06196554: Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs |
|
|
| Recruiting | N/A | 40 | RoW | Oxaliplatin, Irinotecan (SN-38), 5-Fluorouracil, Paclitaxel, Pembrolizumab, Nivolumab | Dong Bing Zhao | Gastric Cancer, Organoid, Neoadjuvant Therapy | 06/24 | 06/24 | | |
ChiCTR2000038709: An Umbrella Study to Explore Precision Treatment of Colorectal Cancer Based on Molecular Typing |
|
|
| Not yet recruiting | N/A | 128 | | PD-L1 monoclonal antibody+HER2 monoclonal antibody+HER2 TKI ;HER2 TKI+Investigator assigned chemotherapy ;Cetuximab + MEK Inhibitor ;PARP Inhibitor + Irinotecan | Shanghai Oriental Hospital; Shanghai Oriental Hospital, Expenditure of department | Colorectal Cancer | | | | |
NCT06322147: Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer |
|
|
| Recruiting | N/A | 50 | RoW | Doublet or triplet chemotherapy combined with cetuximab | Qilu Hospital of Shandong University | Colon Cancer | 12/24 | 12/25 | | |
FIRELIGHT, NCT06169202: A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients |
|
|
| Recruiting | N/A | 50 | RoW | fruquintinib, elunate, Irinotecan, kaiputuo, Capecitabine, xiluoda | China Medical University, China | Fruquintinib, Irinotecan, Capecitabine, Gastrointestinal Tumours | 04/25 | 06/25 | | |
ChiCTR2000035413: A clinical study on the efficacy and safety of Sintilimab in combination with chemotherapy in patients with extensive-stage small-cell lung cancer after failed to platinum-based doublet chemotherapy |
|
|
| Recruiting | N/A | 30 | | Sintilimab+Irinotecan | Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University, Wu Jieping fund | small cell lung cancer | | | | |
| Recruiting | N/A | 478 | Europe | XELOX regimen according to standard procedures, FOLFOX regimen according to standard procedures, Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE), stereotactic body radiation therapy (SBRT), Bevacizumab, tumor biopsy | Radboud University Medical Center, Erasmus Medical Center | Multi-organ Metastatic Colorectal Cancer | 07/23 | 07/25 | | |
MULTIDOM, NCT04263948: Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Plateform |
|
|
| Recruiting | N/A | 42 | Europe | Picado system internet platform and connected objects | Ramsay Générale de Santé, Faculty of Medicine Paris Saclay University, Altran, Assistance Publique - Hôpitaux de Paris | Pancreas Cancer | 07/23 | 12/25 | | |
| Recruiting | N/A | 349 | RoW | CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy | Sun Yat-sen University, Guangzhou Burning Rock Dx Co., Ltd. | Colorectal Cancer | 07/28 | 07/28 | | |
ChiCTR2000032875: A multicenter randomized controlled clinical study of Fuzheng Xiaoji pill in the treatment of metastatic pancreatic cancer |
|
|
| Recruiting | N/A | 368 | | best supportive treatment and Fu-Zheng-Xiao-Ji pill ;best supportive treatment and FOLFIRINOX | Guang'anmen Hospital, China Academy of Chinese Medical Sciences; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 北京市科学技术委员会 | Pancreatic cancer | | | | |
NCT05889325: To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases |
|
|
| Not yet recruiting | N/A | 100 | RoW | DEB-TACE plus HAIC | Peking University Cancer Hospital & Institute | Colorectal Liver Metastases (CRCLM) | 09/23 | 11/23 | | |
NCT06389552: Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients |
|
|
| Recruiting | N/A | 36 | RoW | | HK inno.N Corporation | Adjuvant Chemotherapy | 12/26 | 12/27 | | |
NCT05821582: Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens |
|
|
| Withdrawn | N/A | 8 | US | Stool Collection and Survey Completion | Sanguine Biosciences | Colorectal Cancer | 10/23 | 10/23 | | |
ChiCTR2300074030: Establishment of a biomarker model to predict the efficacy and recurrence risk of targeted drugs combined mFOLFOXIRI in the treatment of unresectable advanced rectal cancer |
|
|
| Recruiting | N/A | 32 | | No | Peking University Shougang Hospital; Peking University Shougang Hospital, Peking University Shougang Hospital | Colorectal cancer | | | | |
ChiCTR2100045399: TCM evidence-based capacity building and evidence-based implementation plan of TCM combined with chemotherapy in treatment of metastatic colorectal cancer:A bidirectional cohort study of Zhenqiliujun anti-cancer granules combined with mFOLFOX6/FOLFIRI regimen and bevacizumab/cetuximab in first-line treatment of advanced metastatic colorectal |
|
|
| Recruiting | N/A | 362 | | MFOLFOX6 /FOLFIRI regimen + bevacizumab/cetuximab + Zhenqi Liujun cancer suppressant granules. ;MFOLFOX6 /FOLFIRI + bevacizumab/cetuximab | Department of Oncology, Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University; The Traditional Chinese Medicine Hospital Affiliated to Southwest, National Administration ofnTraditional Chinese Medicine | colorectal cancer | | | | |
ChiCTR2300073831: Personalized use of irinotecan in colorectal cancer patients based on real world studies and pharmacogenomics |
|
|
| Recruiting | N/A | 480 | | None ;None ;None | Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital; Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Key R&D Program of Science and Technology Department of Sichuan Province（Major science and technology projects）（2022YFS0272） | colorectal cancer | | | | |
DEBIRI, NCT06177288: Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Metastases |
|
|
| Not yet recruiting | N/A | 39 | RoW | DEBIRI Combined With Chemotherapy and Bevacizumab | Fudan University | Colorectal Neoplasms | 01/25 | 05/25 | | |
PDAC-LIV, NCT06349278: Pancreatic Cancer and Synchronous Liver Metastases Resection Following Neoadjuvant FOLFIRINOX |
|
|
| Recruiting | N/A | 15 | Canada | Pancreatic resection and non-anatomic liver resections. | Laval University | Pancreas Adenocarcinoma, Pancreas Metastases, Pancreas Cancer | 01/26 | 01/29 | | |
SALVLIV, NCT06199232: Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment |
|
|
| Recruiting | N/A | 47 | RoW | HAIC+targeted therapy+PD-1 inhibitor, HAIC+Fruquintinib/Cetuximab+Tislelizumab | Peking University | Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment | 01/26 | 01/27 | | |
PACsign, NCT05475366: Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures |
|
|
| Recruiting | N/A | 62 | Europe | Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies) | Institut Curie | Carcinoma, Pancreatic Ductal, Prognosis | 12/26 | 12/26 | | |
NCT05959395: Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors |
|
|
| Recruiting | N/A | 5 | US | VectRx Thermal Therapy | NeoTherma Oncology, University of Maryland, Baltimore, Databean | Pancreatic Cancer | 02/24 | 04/24 | | |
VALIDATE, NCT03043950: Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line |
|
|
| Completed | N/A | 647 | Europe | Panitumumab, + FOLFIRI or FOLFOX | iOMEDICO AG, Amgen | Metastatic Colorectal Cancer, RAS Wild-type | 01/24 | 01/24 | | |
SMART, NCT04276857: Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | N/A | 27 | NA | Irreversible electroporation (NanoKnife® ), FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) or gemcitabine/nab-paclitaxel | University of Saskatchewan | Locally Advanced Pancreatic Cancer, Irreversible Electroporation | 03/26 | 03/26 | | |
NCT06364046: Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC |
|
|
| Not yet recruiting | N/A | 56 | RoW | Drug-eluting beads bronchial arterial chemoembolization, Serplulimab, Intravenous chemotherapy | The Central Hospital of Lishui City | Carcinoma, Small Cell Lung Cancer | 12/24 | 12/25 | | |
cmPAT, NCT06167967: Circulating Tumor DNA Methylation Guiding Postoperative Adjuvant Chemotherapy in Stage III Colorectal Cancer |
|
|
| Recruiting | N/A | 990 | RoW | ctDNA methylation, standard treatment | Sir Run Run Shaw Hospital | Colorectal Cancer | 12/26 | 12/29 | | |
ST-Y90-CP01, NCT06447727: Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM |
|
|
| Recruiting | N/A | 30 | RoW | SIRT with Yttrium-90 Microspheres, FOLFIRI and Bevacizumab | Zhongda Hospital | Colorectal Cancer Metastatic | 11/25 | 11/25 | | |
NCT06463548: Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma |
|
|
| Not yet recruiting | N/A | 30 | RoW | irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin, Lenvatinib, lunfatini | Yunpeng Liu, CSPC Ouyi Pharmaceutical Co., Ltd. | Biliary Tract Carcinoma | 12/25 | 12/26 | | |
NCT04926545: XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study) |
|
|
| Recruiting | N/A | 24 | RoW | Xiao Chai Hu Tang (XCHT), Xiao Chai Hu Tang granules from Nin Jiom Medicine Manufactory (Hong Kong) Ltd., Raloxifene, Evista from Eli Lilly, FOLFIRI regimen, Irinotecan Hydrochloride from Pfizer+Folinic acid+5-fluorouracil (5-FU) | Guangzhou University of Traditional Chinese Medicine, University of Houston | Malignant Tumor, Diarrhea | 09/24 | 10/24 | | |
NCT01595321: Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas |
|
|
| Active, not recruiting | N/A | 19 | US | Cyclophosphamide, Cytoxan, PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine, Pancreatic cancer vaccine, Stereotactic Body Radiation (SBRT), FOLFIRINOX, Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Skip Viragh Foundation | Pancreatic Cancer | 09/24 | 09/24 | | |
| Recruiting | N/A | 300 | Europe | Gemcitabine, Folfirinox, Gemcitabine - nab-paclitaxel, Fluorouracil, FLOX, 5-FU, 5-Fluorouracil | Lund University | Periampullary Adenocarcinoma, Periampullary Cancer, Pancreatic Cancer | 09/26 | 09/27 | | |
NCT05424692: Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer |
|
|
| Recruiting | N/A | 200 | RoW | 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate, PTC drug sensitivity results | Peking Union Medical College Hospital | Colon Cancer, Rectal Cancer, Chemotherapy Effect, PTC, Exon Mutation | 09/24 | 09/26 | | |
NCT06071052: TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens |
|
|
| Not yet recruiting | N/A | 21 | RoW | TACE and HAIC Combined With Regorafenib | First Affiliated Hospital, Sun Yat-Sen University | Liver Metastasis Colon Cancer | 11/24 | 11/24 | | |
| Not yet recruiting | N/A | 100 | NA | | National Taiwan University Hospital | The Influence of the UGT1A1 Genotype | 12/24 | 12/24 | | |
NCT06055179: XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial) |
|
|
| Recruiting | N/A | 98 | RoW | Xiao Chai Hu Tang (XCHT), Xiao Chai Hu Tang granules from Nin Jiom Medicine Manufactory (Hong Kong) Ltd, Placebo, Placebo provided by Nin Jiom Medicine Manufactory (Hong Kong) Ltd, Irinotecan regimen, Raloxifene | Guangzhou University of Traditional Chinese Medicine, University of Houston | Xiao Chai Hu Tang, Irinotecan-induced Diarrhea | 12/24 | 02/25 | | |
ChiCTR1900027801: The prospective, randomized, multicenter clinical study of the efficacy and safety of Raltitrexed combined with Irinotecan(SALIRI) compared with FOLFIRI second-line treatment in the treatment of advanced colorectal cancer |
|
|
| Recruiting | N/A | 429 | | SALIRI ;FOLFIRI | Bangwei Cao; Beijing Friendship Hospital, Capital Medical University, Beijing digestive department Collaborative Development Center | colorectal cancer | | | | |
NCT05362825: Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer |
|
|
| Recruiting | N/A | 89 | RoW | Neo-adjuvant Chemotherapy FOLFOXIRI Regimen, synchronous resection surgery, Liver-first surgery, Primary/Bowel-first Surgery, No surgery | Cho Ray Hospital, University of Medicine and Pharmacy at Ho Chi Minh City | Liver Metastasis Colon Cancer, Synchronous Neoplasm | 12/24 | 01/25 | | |
NCT05352165: The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer |
|
|
| Not yet recruiting | N/A | 192 | NA | standard long-term therapy, FOLFOX and standard long-term radiotherapy, FOLFIRI and standard long-term radiotherapy, 5-FU and standard long-term radiotherapy, 5-FU and pembrolizumab and standard long-term radiotherapy, Other individualized treatments | Shanghai Minimally Invasive Surgery Center, Shanghai OneTar Biomedicine Co., Ltd., Wuxi Branch of Ruijin Hospital | Neoadjuvant Therapy | 12/24 | 12/25 | | |
NCT05601323: A Study of Suizenji in Patients With Unresectable Pancreatic Cancer |
|
|
| Recruiting | N/A | 90 | Japan | Suizenji, Nal-IRI/FL, mFOLFIRINOX, Gem/nab-PTX | SONIRE Therapeutics Inc. | Unresectable Pancreatic Cancer | 10/25 | 10/25 | | |
NCT05649163: Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy |
|
|
| Not yet recruiting | N/A | 306 | RoW | Disitamab Vedotin, RC48 | Shen Lin, RemeGen Co., Ltd. | HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumor | 01/25 | 05/25 | | |
NCT05832398: Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer |
|
|
| Recruiting | N/A | 186 | RoW | FOLFOX , FOLFIRI or FOLFOXIRI regimens, oxaliplatin, irinotecan, 5-fluorouracil, FOLFOX or CapeOX regimens, oxaliplatin, 5-fluorouracil | Nanfang Hospital, Southern Medical University, Sixth Affiliated Hospital, Sun Yat-sen University, Sun Yat-sen University | Colorectal Cancer | 01/25 | 12/25 | | |
PeRFormanCe, NCT05298722: Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy ( Trial) |
|
|
| Recruiting | N/A | 45 | Europe | Imaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires., Analysis of imaging with radiomics and genetic analysis of peripheral blood samples (liquid biopsy) | University Hospital, Ghent | Pancreatic Cancer | 03/25 | 03/26 | | |
NCT05731336: A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan. |
|
|
| Recruiting | N/A | 500 | RoW | | Sun Yat-sen University | Advanced Colorectal Cancer | 05/25 | 05/26 | | |
NCT05928312: Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 72 | RoW | Fruquintinib Combined With Chemotherapy, Fruquintinib oxaliplatin irinotecan | Zhejiang Cancer Hospital | Advanced Colorectal Cancer | 06/25 | 06/26 | | |
NCT06021015: Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLM |
|
|
| Not yet recruiting | N/A | 72 | NA | Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）, Irinotecan and HepaSphere Microspheres | Zhongda Hospital | Colorectal Cancer Liver Metastasis | 06/25 | 12/25 | | |
NCT05354674: Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis |
|
|
| Not yet recruiting | N/A | 302 | RoW | Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 07/25 | 07/28 | | |
NCT05978349: PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer |
|
|
| Recruiting | N/A | 150 | RoW | adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro, PTC drug sensitivity results | Peking Union Medical College Hospital | Colo-rectal Cancer | 09/25 | 09/25 | | |
NCT05655780: The Role of the Tumor Molecular Profile (CMS), UGT1A1 Genotype and Beta-glucuronidase Activity of the Intestinal Microbiota for Treatment Efficiency, Toxicity, Survival and Quality of Life in Patients With Metastatic or Unresectable Colorectal Cancer During Irinotecan-based Systemic Treatment |
|
|
| Recruiting | N/A | 104 | Europe | | Maastricht University Medical Center, Maastricht University, Wageningen University & Research, Fontys Hogeschool, Amsterdam UMC - Locatie AMC, Erasmus Medical Center, Catharina Ziekenhuis, University of North Carolina (USA), Oncology patientenpanel MUMC, Stichting Kanker.nl, Van Weel-Bethesda Ziekenhuis, VieCuri Medisch Centrum voor Noord-Limburg, Gelderse Vallei Hospital, Danone Nutricia Research, Clinical Trial Center Maastricht B.V., Dutch Colorectal Cancer Group (DCCG), Prospectief Landelijk CRC Cohort (PLCRC), CRC-guideline committee, CZ zorgverzekeraar, Landelijke Werkgroep Diëtisten Oncologie (LWDO) | Colorectal Neoplasms | 10/25 | 12/28 | | |
NCT05583422: Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy |
|
|
| Recruiting | N/A | 96 | US | DPYD or UGT1A1 variants | University of Michigan Rogel Cancer Center | Cancer | 12/25 | 12/25 | | |
ChiCTR2000030600: Study on the safety and effectiveness of cytoreductive surgery for colorectal cancer peritoneal metastasis patients who are sensitive to the first-line chemotherapy of FOLFOXIRI combined with bevacizumab |
|
|
| Recruiting | N/A | 39 | | FOLFOXIRI, bevacizumab combined with cytoreductive surgery | The Sixth Affiliated Hospital, Sun Yat-Sen University; The Sixth Affiliated Hospital, Sun Yat-sen University, PI self-financing | synchronous peritoneal metastasis in colorectal cancer | | | | |
NCT05780684: Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer |
|
|
| Recruiting | N/A | 36 | US | FOX dose-escalation algorithm | Dartmouth-Hitchcock Medical Center | Colorectal Cancer, Esophagus Cancer, Appendix Cancer, Small Bowel Cancer, Ampullary Cancer | 11/25 | 05/26 | | |
NCT05189171: MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer |
|
|
| Completed | N/A | 46 | US | MicroOrganoSphere (MOS) drug screen | Xilis, Inc. | Colorectal Neoplasms | 11/23 | 03/24 | | |
NeoPancOne, NCT04472910: GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 84 | Canada | Modified Folforinox (mFFX), Folfirinox or other approach | University Health Network, Toronto, Pancreatic Cancer Canada | Resectable Pancreatic Cancer | 12/25 | 12/25 | | |
ChiCTR2100044562: A trial for construction of gallbladder carcinoma organoids database, individual drug sensitivity test and combined immunotherapy |
|
|
| Not yet recruiting | N/A | 90 | | Treating with Gemcitabine and GEMOX ;Treating with Fluorouracil and GEMOX ;Treating with Cis-platinum and GEMOX ;Treating with Gemcitabine and FOLFIRINOX ;Treating with Fluorouracil and FOLFIRINOX ;Treating with Cis-platinum and FOLFIRINOX ;Treating with Gemcitabine ;Treating with Fluorouracil ;Treating with Cis-platinum | Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University, School of Medicine, Self financing by researchers | gallbladder carcinoma | | | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
ChiCTR1900022856: Clinical study for embolization of intrahepatic cholangiocarcinoma with irinotecan loaded with polyvinyl alcohol embolic microspheres |
|
|
| Completed | N/A | 40 | | Irinotecan loaded on drug-loaded microspheres ;Lipiodol embolization combined with irinotecan infusion chemotherapy | Intervention Department, Fifth Medical Center, General Hospital of PLA; Fifth Medical Center of PLA General Hospital, Self financing | Intrahepatic cholangiocarcinoma | | | | |
NCT06048146: A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis |
|
|
| Enrolling by invitation | N/A | 180 | RoW | Experimental: FOLFOXIRI and Lateral lymph node dissection, Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin, Intestinal Neoplasms, Gastrointestinal Neoplasms, Rectal Diseases, Rectal Neoplasms | 09/27 | 09/29 | | |
GemSign-01, NCT06046794: Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients |
|
|
| Not yet recruiting | N/A | 100 | NA | Analyze of GemCore status | Institut Paoli-Calmettes | Cancer Of Pancreas | 11/27 | 11/27 | | |
NCT06122480: Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | N/A | 40 | US | Surgery | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease | 12/27 | 04/28 | | |
ADAPTA, NCT06068023: The Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. |
|
|
| Recruiting | N/A | 400 | Europe | Folfirinox, leucovorin calcium (folinic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin., Capox, Capecitabine and oxaliplatin | Fondazione Poliambulanza Istituto Ospedaliero, Associazione Italiana per la Ricerca sul Cancro | Ampullary Adenocarcinoma | 07/28 | 07/29 | | |
